GlassScriptPhysician profile
Steven C Nelson
NPI 1164486908
$12,502.07
in general payments reported to CMS, 2019-2025
78 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,526 · 2020: $1,578 · 2021: $2,090 · 2022: $1,741 · 2023: $1,979 · 2024: $1,699 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,566.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,047.70 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,485.96 | 2019-2025 | |
| Novo Nordisk INC | $1,483.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,045.76 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $801.65 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $584.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $421.79 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $390.15 | 2019-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $337.85 | 2019-2024 | Xarelto, Spravato |
| Amgen INC. | $248.59 | 2019-2025 | Otezla, Repatha, Otezla |
| Antares Pharma, INC. | $236.05 | 2020-2025 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $227.86 | 2019-2024 | Steglatro, Belsomra, Gardasil |
| Abbott Laboratories | $171.98 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $158.66 | 2019-2021 | |
| Astellas Pharma US INC | $146.04 | 2019-2025 | Veozah, Myrbetriq |
Show all 78 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Nelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.